MGMT and glioblastoma: The reproducibility of MGMT as a predictive biomarker will be prospectively validated as part of the ongoing EORTC/NCI/RTOG (EORTC protocol 26052–22053) phase III study comparing conventional adjuvant temozolomide with dose-intense temozolomide in patients with newly diagnosed glioblastoma.